Pivekimab sunirine, a novel CD-123 antibody drug conjugate is approved for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Also, what the heck is BPDCN?
Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
